I'm just wondering if there is anyone with experience using CM-H2DCFDA for the detection of reactive oxygen species that could answer some questions? My work is in the field of diabetes and I need to measure endogenous ROS islets (a cluster of cells) as well as after certain treatments (e.g. H2O2). I'll be measuring the DCF fluorescence using a fluorescence plate reader (FLUOstar Optima) rather than microscopy or flow cytometry. The problem I face is that islets are in suspension in the media, hence I will need to adapt the ROS assay protocols made for cell monolayers. Here are my questions:
1/ Do you add the probe to the cells before or after the treatment regime? I have been told by an expert in ROS assays with CM-H2DCFDA that you must always add the probe after the treatment as "dead cells don't produce ROS" and hence if the probe is already present inside the cells then the ROS accumulation in the dead cells will be captured. On the other hand, I have read on this forum that because cells don't "like" the probe they will spit it out and so it is better to add the probe just prior to measuring fluorescence in the plate reader.
2/Will sonication of cells after probe addition dramatically increase your signal? I ask this because I'm unsure whether you can get an accurate readout from an intact cluster of cells like the islet.
3/ Does anyone have an understanding of gain adjustment with regards to fluorescence readings?
Hopefully there will be some good advice coming my way.
Cheers,
Massiveattack













